KalVista Pharmaceuticals, Inc. (KALV) Reports Q3 Loss, Tops Revenue Estimates
KalVista Pharmaceuticals (KALV) delivered earnings and revenue surprises of +4.17% and +242.30%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?